STERIS’s Fiscal 2026 Close: A Clean Sweep on Revenue and EPS, with a $1B Buyback on the Table

Ticker: NYSE: STE • EPS (GAAP and adjusted) highlighted; revenue forecast not issued, but the company shows momentum. Analysts will soon compare against EPS consensus and what constitutes an earnings surprise — if any — in their notes.

Executive snapshot

STERIS plc reported fiscal 2026 results that look more like a well-tuned instrument than a scraped-together one. For the year ended March 31, 2026, the company posted 9% growth in revenue from continuing operations to about $5.9 billion, with constant currency organic growth of roughly 7%. The fourth quarter added a similar rhythm: revenues of $1.6 billion, up 7% year over year, aided by a 5% organic gain in constant currency. On the profit side, GAAP net income for the full year came in at $782.3 million or $7.93 per diluted share, while an adjusted figure stood at about $1.0 billion or $10.17 per diluted share. In Q4, GAAP earnings per share were $2.24 and adjusted EPS was $2.83.

Management also announced a new $1 billion share repurchase program, signaling confidence in cash generation and a desire to lean into capital returns even as the business navigates tariff headwinds and inflation risks that continue to tug at margins.

What drove the numbers

The results sit at the intersection of solid end-market demand and prudent operating leverage. In the fourth quarter, healthcare revenue rose to about $1.14 billion, a 7% reported increase with 9% service revenue growth, 7% consumables growth, and a 6% uptick in capital equipment revenue. Constant currency organic growth in Healthcare was 6%. Applied Sterilization Technologies (AST) contributed meaningfully, with Q4 revenue of about $289.2 million, up 6% as reported, driven by a 10% lift in service revenue and a large swing—the 62% drop in capital equipment revenue—reflecting a timing and mix dynamic rather than a fundamental issue. AST operating income in Q4 reached roughly $131.1 million, supported by price realization offsetting some negative volume effects from capital equipment declines.

Life Sciences, another line within the company’s portfolio, posted a quarterly revenue increase of about 9% to roughly $162.9 million, signaling broader demand beyond core healthcare sterilization services.

On the cost side, margins were pressured by tariffs and inflation, but the company’s revenue growth and price discipline helped offset much of that headwind. The result is a non-trivial gap between GAAP and adjusted figures in both the quarter and the full year, a reminder that Steris continues to apply a different lens to measure cash earnings versus reported earnings.

Segment highlights

Healthcare remained the largest growth engine, delivering revenue growth and a stable operating income foundation. The segment’s operating income for the quarter stood at approximately $283.2 million, versus $279.7 million in the prior year’s Q4, underscoring incremental operating leverage when volume and pricing align with inflationary costs.

AST continued to demonstrate service-led growth, with the Q4 revenue improvement supported by ramping service activities, even as capital equipment revenues contracted. The mix in AST—higher services, lower capital cadence—suggests management is balancing near-term revenue mix with longer-term service-based revenue durability.

Life Sciences added to the ensemble with a solid 9% quarterly gain, illustrating breadth beyond Steris’s sterilization core and hinting at a positive cross-segment corporate cadence as customers invest in end-to-end life sciences workflows.

Capital allocation and strategy

In a move that reads like a vote of confidence, the board authorized a new $1 billion share repurchase program. The decision aligns with a broader shareholder-friendly posture: buybacks can support earnings per share by offsetting share count increases and signaling management’s comfort with free cash flow generation, even if the current macro environment remains uncertain in the near term.

Taken together, the capital allocation signal complements the cash-flow profile implied by the earnings numbers. While no formal revenue forecast guidance was issued, the combination of steady organic growth, a diversified healthcare services mix, and an active buyback program suggests management is not counting on a single macro move to lift results; instead, it’s aiming for a sustainable trajectory with optionality baked in via repurchases.

Market implications and sector peers

For the sector, Steris’s performance underscores the durability of demand in healthcare services and sterilization technologies, even as inflation and tariffs create crosswinds. EPS momentum matters as much for the stock’s multiple as it does for the company’s ability to fund growth and returns. Investors will be watching EPS consensus vs. actuals and whether the 10.17 adjusted EPS for the year translates into sustainable free cash flow in 2027.

Peers in the healthcare-sterilization space and broader life sciences tools universe will gauge whether Steris’s revenue mix—services-driven with steady consumables and a partial revival in capital equipment—can be replicated in different geographies or product cycles. If Steris can sustain operating leverage as input costs normalize, others with similar cost structures may look to reaccelerate margins. Conversely, any persistence of tariff-driven cost pressures could compress margins for peers with higher exposure to capital equipment cycles or to regions sensitive to FX swings.

Bottom line

STERIS’s fiscal 2026 finish presents a clean narrative: revenue growth across core segments, meaningful EPS gains, and a ready-to-use buyback engine. The 4Q numbers show resilience in Healthcare and a balanced contribution from AST and Life Sciences, with adjusted earnings comfortably outpacing the GAAP baseline in the full year. The absence of explicit forward revenue guidance keeps the stock’s short-term narrative tethered to execution rather than forecasted growth, but the buyback program injects a practical confidence signal to investors who care about per-share metrics as a proxy for long-run cash returns.

For STE holders and sector peers, the takeaway is less about any one quarter beating a guess and more about the durability of Steris’s business model amid inflation, tariffs, and shifting healthcare workflows. The question now becomes: can Steris translate this operating tempo into sustained free cash flow and an even more resilient EPS trajectory, even as the macro backdrop remains unsettled?